Clinical efficacy of aboxitinib in the treatment of acute eczema and its influence on the expression of CC chemokine 27 and thymic stromal lymphopoietin
Clinical efficacy of aboxitinib in the treatment of acute eczema and its influence on the expression of CC chemokine 27 and thymic stromal lymphopoietin
Objective To study the clinical efficacy of abucicitinib in the treatment of acute eczema and its effect on the expression of ser-um CC chemokine 27(CCL 27)and thymic stromal lymphopoietin(TSLP)in patients.Methods A retrospective analysis was used on 110 pa-tients with acute eczema admitted to Shanghai Dermatology Hospital from December 2022 to December 2023.They were divided into the study group(n=55)and the control group(n=55)according to different treatment methods.The study group was treated with loratadine and abucicitinib,and the control group was treated with loratadine alone.Patients in two groups were treated for 12 weeks.The clinical effects,and the eczema area and severity index(EASI)score,pruritus degree of skin lesions[visual analogue scale(VAS)score],serum levels of CCL 27 and TSLP,inflammatory factor expression level before treatment and after 12 weeks of treatment of the two groups were compared,and the drug safety of the two groups of patients during treatment was recorded.Results The overall response rate of patients in the study group was 94.55％,which was significantly higher than that in the control group(72.73％),and the difference was statistically significant(P＜0.05).After 12 weeks of treatment,the EASI and VAS scores of the two groups were significantly lower than those before treatment,and the EASI and VAS scores of the study group were(1.83±0.92)and(1.76±0.55)points,respectively,which were significantly lower than those of the control group[(2.65±1.01)and(3.34±0.82)points],the differences were statistically significant(P＜0.05).After 12 weeks of treatment,the levels of serum CCL27 and TSLP in the two groups were significantly lower than those before treatment,and the levels of serum CCL27 and TSLP in the study group were(98.72±8.57)pg/mL and(2.21±0.69)ng/mL,respectively,which were significantly lower than those in the control group[(105.54±10.92)pg/mL,(2.56±0.66)ng/mL],the differences were statistically significant(P＜0.05).After 12 weeks of treatment,the levels of serum IL-4 and IL-13 in the two groups were significantly lower than those before treatment,and the levels of serum IL-4 and IL-13 in the study group were(0.14±0.02)ng/L and(25.17±3.16)pg/L,respectively,which were significantly lower than those in the con-trol group[(0.35±0.08)ng/L,(27.43±4.12)pg/L],the differences were statistically significant(P＜0.05).During the treatment peri-od,only one patient in the study group had a mild increase in liver function,unchanged study drug,did not develop serious adverse events,and none of the other patients did not experience significant discomfort.Conclusion Compared with loratadine alone,the treatment of abuxitinib com-bined with loratadine can effectively relieve the clinical symptoms and signs of patients,reduce the area of skin lesions,improve the degree of se-verity and itching of skin lesions,and reduce the serum inflammatory factors and CCL 27 and TSLP content,with good safety.
维普
万方数据